We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials
Read MoreHide Full Article
Veeva Systems (VEEV - Free Report) recently announced that Idorsia Pharmaceuticals Ltd has expanded its use of Veeva Vault Clinical Suite applications. This expansion includes Veeva Vault Clinical Data Management Suite (“CDMS”) for electronic data capture and coding.
Being a biopharmaceutical company with a broad portfolio of novel drugs in its pipeline, Idorsia is currently aiming to use Vault CDMS for all new trials.
The growing adoption of Veeva Systems’ applications is expected to provide a significant boost to the company’s Veeva Vault Clinical suite, a component of the broader Veeva Development Cloud product line of the company’s Life Sciences segment.
Significance of the Adoption
Veeva Systems’ Vault CDMS provides an advanced cloud application suite that is expected to enable Idorsia to expedite its study builds and speed up trial execution. Idorsia’s management believes that the partnership with Veeva Systems will provide greater speed and agility to its clinical trials, given the growing complexity of trial design and rise of clinical data sources.
Per Veeva Systems’ management, the adoption of its cloud application suite will likely support Idorsia’s clinical systems strategy with modern applications that can match up with the pace and complexity of present-day studies.
Industry Prospects
Per a report by Marketsandresearch.biz, the global clinical data management system market was estimated to be $1574.8 million in 2021 and is projected to reach $4294.1 million by 2028 at a CAGR of 15.4%. Factors like a surge in clinical trials, a flourishing healthcare industry and increasing research collaborations and partnerships are expected to drive the market.
Given the market potential, growing adoption of the company’s applications is expected to strengthen its position in the global cloud application space.
Recent Developments
Last month, Veeva Systems’ Veeva Development Cloud was selected by the Lymphoma Academic Research Organization to enhance operational efficiency across its lymphoma therapy research.
In December 2021, Veeva Systems’ Veeva Data Cloud was adopted by hematology/oncology therapy developer, PharmaEssentia. The adoption is aimed at supporting the launch of PharmaEssentia’s BESREMi — a latest therapy for polycythemia vera, a rare type of blood cancer.
The same month, Veeva Systems acquired Veracity Logic — a cloud software provider for randomization and trial supply management. Veracity Logic will join Veeva Systems to provide industry-leading software and services that can enable companies to streamline complex processes and accelerate clinical trials.
Price Performance
Shares of Veeva Systems have lost 26.5% in the past year versus the industry’s 48.7% fall and the S&P 500's 14.3% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Baxter International Inc. (BAX - Free Report) , Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
Baxter has gained 7.9% against the industry’s 17.3% fall over the past year.
Allscripts has an estimated long-term growth rate of 11.1%. MDRX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 34.1%. It currently carries a Zacks Rank #2.
Allscripts has gained 26.1% against the industry’s 53.5% fall over the past year.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.5%. It currently has a Zacks Rank #2.
AMN Healthcare has gained 28.2% against the industry’s 58.5% fall over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Veeva Systems (VEEV) Vault CDMS to Aid Idorsia's Clinical Trials
Veeva Systems (VEEV - Free Report) recently announced that Idorsia Pharmaceuticals Ltd has expanded its use of Veeva Vault Clinical Suite applications. This expansion includes Veeva Vault Clinical Data Management Suite (“CDMS”) for electronic data capture and coding.
Being a biopharmaceutical company with a broad portfolio of novel drugs in its pipeline, Idorsia is currently aiming to use Vault CDMS for all new trials.
The growing adoption of Veeva Systems’ applications is expected to provide a significant boost to the company’s Veeva Vault Clinical suite, a component of the broader Veeva Development Cloud product line of the company’s Life Sciences segment.
Significance of the Adoption
Veeva Systems’ Vault CDMS provides an advanced cloud application suite that is expected to enable Idorsia to expedite its study builds and speed up trial execution. Idorsia’s management believes that the partnership with Veeva Systems will provide greater speed and agility to its clinical trials, given the growing complexity of trial design and rise of clinical data sources.
Per Veeva Systems’ management, the adoption of its cloud application suite will likely support Idorsia’s clinical systems strategy with modern applications that can match up with the pace and complexity of present-day studies.
Industry Prospects
Per a report by Marketsandresearch.biz, the global clinical data management system market was estimated to be $1574.8 million in 2021 and is projected to reach $4294.1 million by 2028 at a CAGR of 15.4%. Factors like a surge in clinical trials, a flourishing healthcare industry and increasing research collaborations and partnerships are expected to drive the market.
Given the market potential, growing adoption of the company’s applications is expected to strengthen its position in the global cloud application space.
Recent Developments
Last month, Veeva Systems’ Veeva Development Cloud was selected by the Lymphoma Academic Research Organization to enhance operational efficiency across its lymphoma therapy research.
In December 2021, Veeva Systems’ Veeva Data Cloud was adopted by hematology/oncology therapy developer, PharmaEssentia. The adoption is aimed at supporting the launch of PharmaEssentia’s BESREMi — a latest therapy for polycythemia vera, a rare type of blood cancer.
The same month, Veeva Systems acquired Veracity Logic — a cloud software provider for randomization and trial supply management. Veracity Logic will join Veeva Systems to provide industry-leading software and services that can enable companies to streamline complex processes and accelerate clinical trials.
Price Performance
Shares of Veeva Systems have lost 26.5% in the past year versus the industry’s 48.7% fall and the S&P 500's 14.3% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Veeva Systems carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Baxter International Inc. (BAX - Free Report) , Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .
Baxter, having a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 9.5%. BAX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter has gained 7.9% against the industry’s 17.3% fall over the past year.
Allscripts has an estimated long-term growth rate of 11.1%. MDRX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 34.1%. It currently carries a Zacks Rank #2.
Allscripts has gained 26.1% against the industry’s 53.5% fall over the past year.
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.5%. It currently has a Zacks Rank #2.
AMN Healthcare has gained 28.2% against the industry’s 58.5% fall over the past year.